Outlook Therapeutics (OTLK)
0.56
+0.04 (7.69%)
Upcoming Events
Latest Headlines
Form SCHEDULE 13G Outlook Therapeutics, Filed by: Empery Asset Management, LP
October 13, 2026 12:47 PM - SEC Filing
Outlook Therapeutics names Greg DiPasquale as CCO ahead of U.S. launch
October 9, 2026 8:30 AM - StreetInsider
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
October 9, 2026 8:30 AM - StreetInsider
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
October 6, 2026 9:20 AM - StreetInsider
Outlook Therapeutics files for permanent J-code for Lytenava with CMS
October 1, 2026 9:02 AM - StreetInsider
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
October 1, 2026 9:01 AM - StreetInsider
Form 8-K Outlook Therapeutics, For: Sep 25
September 30, 2026 4:30 PM - SEC Filing
Form 8-K Outlook Therapeutics, For: Sep 16
September 18, 2026 4:31 PM - SEC Filing
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
September 11, 2026 7:00 AM - StreetInsider
Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch
September 10, 2026 9:10 AM - StreetInsider
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
September 10, 2026 9:10 AM - StreetInsider
Form 8-K Outlook Therapeutics, For: Aug 23
August 27, 2026 4:11 PM - SEC Filing
Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch
August 27, 2026 4:05 PM - StreetInsider
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
August 27, 2026 4:05 PM - StreetInsider
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
August 27, 2026 9:01 AM - StreetInsider
Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.
August 19, 2026 1:47 PM - SEC Filing
Form 10-Q Outlook Therapeutics, For: Jun 30
August 18, 2026 5:30 PM - SEC Filing
Outlook Therapeutics Inc. (OTLK) PT Lowered to $4 at Brookline Capital Markets
August 18, 2026 3:49 PM - StreetInsider
Form NT 10-Q Outlook Therapeutics, For: Jun 30
August 17, 2026 4:06 PM - SEC Filing
Form 4 Outlook Therapeutics, For: Aug 14 Filed by: Jahr Robert Charles
August 14, 2026 8:58 PM - SEC Filing
Form SCHEDULE 13D/A Outlook Therapeutics, Filed by: GMS Ventures & Investments
August 14, 2026 7:54 PM - SEC Filing
Form 4 Outlook Therapeutics, For: Aug 12 Filed by: Sukhtian Ghiath M.
August 14, 2026 7:53 PM - SEC Filing
Form 4 Outlook Therapeutics, For: Aug 14 Filed by: KENYON LAWRENCE A
August 14, 2026 7:39 PM - SEC Filing
Form 8-K Outlook Therapeutics, For: Aug 12
August 14, 2026 8:37 AM - SEC Filing
Form 424B5 Outlook Therapeutics,
August 14, 2026 8:31 AM - SEC Filing
Form 8-K Outlook Therapeutics, For: Aug 14
August 14, 2026 8:02 AM - SEC Filing
Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
August 14, 2026 7:37 AM - StreetInsider
Outlook Therapeutics posts Q3 loss, eyes U.S. LYTENAVA launch by end of 2026
August 14, 2026 7:15 AM - StreetInsider
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026 7:15 AM - StreetInsider
Outlook Therapeutics prices $55M public offering of stock and warrants
August 12, 2026 9:45 PM - StreetInsider
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026 9:45 PM - StreetInsider
Form 424B5 Outlook Therapeutics,
August 12, 2026 4:50 PM - SEC Filing
Form 8-K Outlook Therapeutics, For: Aug 12
August 12, 2026 4:02 PM - SEC Filing
Outlook Therapeutics launches public offering of stock and warrants
August 12, 2026 4:01 PM - StreetInsider
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
August 12, 2026 4:01 PM - StreetInsider
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
August 6, 2026 8:45 AM - StreetInsider
Form 4 Outlook Therapeutics, For: Jul 29 Filed by: Sukhtian Faisal Ghiath
July 29, 2026 3:20 PM - SEC Filing
Outlook Therapeutics Inc. (OTLK) PT Raised to $1.60 at H.C. Wainwright
July 28, 2026 6:48 AM - StreetInsider
BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
July 27, 2026 6:09 AM - StreetInsider
Form 8-K Outlook Therapeutics, For: Jul 24
July 24, 2026 5:01 PM - SEC Filing
FDA approves Outlook Therapeutics' Lytenava for wet AMD
July 24, 2026 2:40 PM - StreetInsider
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
July 24, 2026 2:40 PM - StreetInsider
Outlook Therapeutics (OTLK) halted, news pending
July 24, 2026 1:40 PM - StreetInsider
Form 8-K Outlook Therapeutics, For: Jul 21
July 24, 2026 6:02 AM - SEC Filing
Form 4 Outlook Therapeutics, For: Jul 21 Filed by: KENYON LAWRENCE A
July 23, 2026 7:50 PM - SEC Filing
Form 4 Outlook Therapeutics, For: Jul 21 Filed by: Jahr Robert Charles
July 23, 2026 7:34 PM - SEC Filing
Full Article List
